# GENESEN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genesen

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.genesenbio.com
- Total disclosed funding: $5M
- Latest round: Series A (Dec 16, 2021)
- Investors on record: 2

## About

Genesen is a biotechnology company focused on developing innovative biopharmaceuticals and diagnostic tools to improve health and wellness, targeting chronic diseases and preventative healthcare solutions.Founded in 2018, Genesen operates from its headquarters in Seoul, South Korea. The company specializes in biotechnological advancements and has successfully secured Series A funding totaling KRW 6 billion in December 2021 from investors ES Investor and K & Investment Partners, marking its position as an investment target. Genesen has completed a total of 1 deal to date.Genesen Bio specializes in providing advanced biotechnological solutions aimed at enhancing health and wellness through its core product offerings. The company’s main focus is on innovative biopharmaceuticals and diagnostic tools designed to address specific health challenges, particularly in the realms of chronic diseases and preventative healthcare. These products are engineered to integrate seamlessly into existing healthcare frameworks, offering end users—ranging from hospitals to individual patients—effective solutions for monitoring and managing health conditions. Genesen Bio's products are marketed in various geographical regions, with a notable presence in North America and Europe, ensuring a broad client base that includes healthcare providers, research institutions, and pharmaceutical companies.The revenue generation model of Genesen Bio is structured around a combination of direct sales and strategic partnerships within the healthcare sector. The company typically engages in B2B transactions, offering its products to hospitals and clinics that utilize them in patient care. Pricing plans are developed based on the specific needs of healthcare institutions, with flagship products providing significant value through their unique capabilities. These transactions are often facilitated through long-term contracts and subscription models that ensure a steady revenue stream. By maintaining relationships with key healthcare stakeholders, Genesen Bio effectively positions itself to capitalize on the growing demand for innovative health solutions.Genesen plans to leverage the recent Series A funding of KRW 6 billion raised in December 2021 to enhance its product development and market expansion strategies. The company is focused on launching new biopharmaceutical products that will cater to emerging health challenges. Additionally, Genesen aims to expand its market presence in Asia and continues to strengthen its foothold in North America and Europe by 2023, targeting specific healthcare institutions that align with its innovative offerings.

## Funding rounds

- Series A, Dec 16, 2021, $5M — ES Investor, K & Investment Partners

## Investors

- ES Investor (https://capitalatlas.ai/funds/es-investor) — Series A
- K & Investment Partners (https://capitalatlas.ai/funds/k-investment-partners) — Series A